Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients With Advanced Solid Tumors

NCT03311334 is registered in ClinicalTrials.gov with Sumitomo Pharma America, Inc. as lead sponsor.

NCT NCT03311334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03311334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients With Advanced Solid Tumors
Lead sponsor
Sumitomo Pharma America, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
December 14, 2017
Completion date
November 29, 2022
Enrollment
47 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, platinum-resistant ovarian cancer (proc), primary peritoneal cancer, renal cell carcinoma (rcc), serous epithelial ovarian cancer, urothelial carcinoma